Form DEFA14A SYNAPTICS Inc
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq set to open higher as AI stocks rebound ahead of earnings rush
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month high with Hormuz transits in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Proxy Statement Pursuant to Section 14(a)
of the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐
Check the appropriate box:
|
☐
|
Preliminary Proxy Statement
|
|
☐
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
Definitive Proxy Statement
|
|
☒
|
Definitive Additional Materials
|
|
☐
|
Soliciting Material under §240.14a-12
|
|
SYNAPTICS INCORPORATED
|
|
(Name of Registrant as Specified in Its Charter)
|
|
|
|
N/A
|
|
(Name of Person(s) Filing Proxy Statement, If Other Than the Registrant)
|
|
|
Payment of Filing Fee (Check all boxes that apply):
|
☒
|
No fee required
|
|
☐
|
Fee paid previously with preliminary materials
|
|
☐
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
|
The following is the cover page of the definitive proxy statement that was first mailed to the stockholders of Synaptics Incorporated (“Synaptics”) on or about October 19, 2026, in connection with the pending acquisition of
Synaptics by ON Semiconductor Corporation:
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KeyBanc's 3Q26 Semiconductor Earnings Preview
- Commentari launches a civic engagement platform to help individuals and organizations participate in federal rulemaking and legislation
- Riboscience to Present First Overall Survival and Immune Activation Data from Phase 1b Study of ENPP1 Inhibitor RBS2418 as Monotherapy and in Combination in Advanced Metastatic Cancers Including MSS C
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
